Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables

 
• By Alaric DeArment
  
Merck announced the initiation of its Phase III program for oral PCSK9 inhibitor MK-0616 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D